ArticleBMC medical informatics and decision making2025
Relationship between C-reactive protein triglyceride glucose index and cardiovascular disease risk: a cross-sectional analysis with machine learning.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study.Cardiovascular diabetology · 2026Article
- Association of triglyceride-glucose related indices with the incidence of venous thromboembolism: a nationwide prospective cohort study based on the UK Biobank.BMC cardiovascular disorders · 2026Article
- Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review.International journal of general medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) continues to be a leading cause of disease burden and mortality worldwide. Identifying reliable biomarkers for CVD risk assessment is essential. This study investigates the association between the C-reactive protein-triglyceride-glucose (CTI) index and CVD, evaluating its potential value in CVD classification.
methodsThis study included 14,899 participants aged 20 years and older from the 1999-2020 National Health and Nutrition Examination Survey. Regression analysis and restricted cubic splines (RCS) were used to examine the relationship between the CTI and CVD, along with its five specific outcomes. An interaction test assessed the impact of different subgroups on the association between CTI and CVD. Furthermore, the potential of CTI to assess CVD risk was evaluated through receiver operating characteristic (ROC) curves, decision curve analysis, and SHAP analysis, with machine learning models, including XGBoost, LASSO, random forest, support vector machine, and Naive Bayes, used for evaluation.
resultsFor each 1-unit higher CTI, the odds of having CVD were 18% higher (OR = 1.18, 95% CI: 1.10-1.28, P < 0.01). Specific associations include congestive heart failure (29%) (OR = 1.29, 95% CI: 1.14-1.47, P < 0.001), heart attack (29%) (OR = 1.29, 95% CI: 1.15-1.44, P < 0.001), coronary heart disease (20%) (OR = 1.20, 95% CI: 1.07-1.35, P < 0.01), angina (21%) (OR = 1.21, 95% CI: 1.06-1.36, P < 0.01), and stroke (13%) (OR = 1.13, 95% CI: 1.01-1.27, P < 0.05). Age influences the association between CTI and CVD, with individuals under 60 years being more affected. Machine-learning models achieved AUC > 0.70, indicating moderate discriminatory ability; these findings suggest promising potential for risk stratification. SHAP analysis indicated that CTI showed larger SHAP contributions to CVD classification than CRP and TyG within our models.
conclusionHigher CTI levels were associated with higher odds of prevalent CVD, indicating that CTI may serve as a marker of CVD status and aid cross-sectional discrimination of prevalent CVD. Prospective longitudinal studies are needed to establish temporality and to evaluate whether CTI adds predictive value in longitudinal risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.